Shares of biotechnology company Rexahn Pharmaceuticals (RNN) are collapsing – down nearly 43% as of this writing. The reason?
When a tumor-targeted therapy company advances in clinical trials, pay attention. Rexahn Pharmaceuticals (NYSEMKT:RNN) should be closely watched.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced the appointment of Lisa Nolan, …
As Intercept Pharmaceuticals Inc (NASDAQ:ICPT) approaches a crucial date for FDA approval of a liver disease treatment and Rexahn Pharmaceuticals, Inc (NYSE:RNN) announces its YE15 earnings …
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, announced the appointment of Peter …
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, announced that Dr.
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, announced that its drug candidate …
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, announced that it presented preclinical …
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today presents preclinical data on …
In a research report released today, MLV analyst Vernon Bernardino initiated coverage on shares of Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) with a Buy rating and …
